Skip to Content

Tapan M. Kadia, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Robert Wood Johnson Medical School, Piscataway, NJ, MD, Doctor of Medicine
1998 Rutgers University, New Brunswick, NJ, BA, Bachelor of Arts

Postgraduate Training

7/2004-6/2005 Chief Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2002-6/2004 Clinical Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2001-6/2002 Clinical Internship, Baylor College of Medicine Affiliated Hospitals, Houston, TX

Board Certifications

8/2004 Internal Medicine, American Board of Internal Medicine

Honors and Awards

2006 AACR/ASCO Workshop Methods in Clinical Cancer Research Vail
2006 AACR/ASCO Workshop Molecular Biology in Clinical Oncology Aspen
2006 FOREM Lymphoma Research Award, Runner up
2006 Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant
2004 Chief Residency, Internal Medicine, Baylor College of Medicine
2000 Articulated BA/MD Program
2000 Dean's List, Rutgers College
2000 Member, Golden Key National Honor Society
2000 Member, Phi Beta Kappa Honor Society
2000 Member, Phi Eta Sigma Honor Society
2000 Recipient of The Waksman Fellowship for Undergraduate Research
2000 UMDNJ Research Fellowship
1998 Norman Reitman Scholoar
1996 Rutgers College Award of Excellence
1995 Rutgers College Award of Excellence

Professional Memberships

American Society of Clinical Oncology (ASCO)
Associate Member, 1/2000
American Society of Hematology (ASH)
Associate Member, 1/2000

Selected Publications

Peer-Reviewed Original Research Articles

1. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 11/2012. e-Pub 5/2012. PMCID: PMC3416961.
2. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. e-Pub 10/2012. PMID: 23115106.
3. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: 22282348.
4. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 9/2012. e-Pub 1/2012. PMID: 22252728.
5. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
6. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 8/2012. e-Pub 6/2012. PMID: 22718840.
7. Borthakur G, Rosenblum M, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich E, Kadia TM, Garcia-Manero G, Kantarjian HM, Cortes J. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients withadvanced myeloid malignancies. Haematologica. e-Pub 8/2012. PMID: 22875630.
8. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: 22534616.
9. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118(14):3556-64, 7/2012. e-Pub 12/2011. PMID: 22139909.
10. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 6/2012. PMID: 22578814.
11. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30(3):1107-15, 6/2012. e-Pub 4/2011. PMID: 21494838.
12. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 6/2012. e-Pub 5/2012. PMID: 22585696.
13. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/2012. PMID: 22360602.
14. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. e-Pub 5/2012. PMID: 22605576.
15. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 5/2012. e-Pub 10/2011. PMID: 22020636.
16. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 3/2012. e-Pub 1/2012. PMCID: PMC3311242.
17. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: clinical outcome analysis of 123 patients. Haematologica 97(2):235-40, 2/2012. e-Pub 11/2011. PMCID: PMC3269483.
18. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/2011. PMID: 22072492.
19. Sharp H, Grosshans D, Kadia T, Dabaja BS. Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia. BMJ Case Rep 2012, 2012. e-Pub 7/2012. PMID: 22787181.
20. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38(5):682-92, 10/2011. PMID: 21943675.
21. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29(23):3173-8, 8/2011. e-Pub 7/2011. PMID: 21747082.
22. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
23. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 11/2010. e-Pub 7/2010. PMID: 20668231.
24. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 10/2010. e-Pub 10/2010. PMID: 20729640.
25. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk 10(4):301-2, 8/2010. PMID: 20709669.
26. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The Combination of a Histone Deacecetylase Inhibitor with the BH3-Mimetic GX15-070 has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clin Cancer Res 16(15):3923-32, 8/2010. e-Pub 6/2010. PMID: 20538760.
27. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72-82, 7/2010. e-Pub 4/2010. PMID: 20456355.
28. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 1/2010. e-Pub 12/2009. PMCID: PMC2815701.
29. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol 94(1):149-52, 8/2009. e-Pub 2/2009. PMID: 19219404.
30. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
31. Kadia TM, Garcia-Manero G. Role of epigenetic therapy in myelodysplastic syndrome. Expert Rev Hematol 1(2):161-174, 12/2008. PMID: 21082921.
32. Mendez J, Kadia TM, Somayazula RK, El-Badawi KI, Cowen DS. Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. J Neurochem 73(1):162-8, 7/1999. PMID: 10386967.

Abstracts

1. H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes, A. Reyes, S. M. O'Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva, E. Jabbour. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO 29(15S) (#6568), 6/2011.
2. A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O'Brien, H. Kantarjian, G. Borthakur, T. M. Kadia, M. Kelly, R. Garris, and S. Faderl. Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). JCO (#6554), 6/2011.
3. A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O'Brien, G. Garcia-Manero, J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. Kantarjian. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. JCO 29(15S) (#6557), 6/2011.
4. E. Jabbour, S. M. O'Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl, T. M. Kadia, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes, H. Kantarjian. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). JCO 29(15S) (#6507), 6/2011.
5. F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. JCO 29(15S) (#6587), 6/2011.
6. G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia, E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel, L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor, J. E. Cortes, H. Kantarjian. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. JCO 29(15) (#6506), 6/2011.
7. T. M. Kadia, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng, J. E. Cortes. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. JCO 29(15S) (#6617), 6/2011.
8. A. Al-Kali, S. N. Konoplev, E. Lin, T. M. Kadia, S. Faderl, F. Ravandi Kashani, M. Ayoubi, M. Brandt, H. Kantarjian, G. Borthakur. Hypocellular acute myeloid leukemia: Better or worse prognosis. JCO 28(15) (#6561), 6/2010.
9. N. Pemmaraju, H. Kantarjian, S. Faderl, G. Garcia-Manero, T. M. Kadia, G. Borthakur, J. E. Cortes, F. Ravandi Kashani. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). JCO 28(15) (#6605), 6/2010.
10. Kadia TM , Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstosvek S, Newsom W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Poster Presentation, American Society of Hematology Meeting, 12/2007.
11. Thompson MA, Kadia TM , Bekele BN, Wang M, Romaguera JE. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Poster Presentation, American Society of Hematology, 12/2007.
12. Kadia TM , Kantarjian H, Verstovesek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. Poster Presentation, American Society of Hematology Meeting, 12/2007.
13. Kadia TM , Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. Phase I Study of the Combination of a DNA Topoisomerase Inhibitor, Idaruicin, with the Histone Daecetylase Inhibitor Vorinostat in Advanced Leukemia. Poster Presentation, American Society of Clinical Oncology Meeting, 5/2007.
14. Kadia TM, Rodriguez A, Fayad L, Mclaughlin P, Pro B. Retrospective Review of Angioimmunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. American Society of Hematology Meeting, 12/2006.
15. Kadia TM , Kleinbaum E. Atypical Cutaneous Presentation of Acute Monocytic Leukemia. Poster Presentation, Baylor College of Medicine Annual Research Symposium, 6/2005.

Last updated: 11/5/2012